Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma
Launched by AARHUS UNIVERSITY HOSPITAL · May 15, 2023
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
**Clinical Trial Summary: Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG-Asparaginase in Children and Adolescents With ALL and Lymphoma**
This clinical trial is studying how certain treatments for acute lymphoblastic leukemia (ALL) and lymphoma might affect blood sugar levels in children and teenagers. While most kids with these conditions have a high chance of survival thanks to effective chemotherapy, some treatments, especially steroids and PEG-asparaginase, can lead to problems with glucose control, which may cause diabetes. The researchers want to find out how often these issues occur and how long they last during treatment. To do this, they will use a small device that continuously measures blood sugar levels and will also take blood samples to better understand how the body is using insulin, a hormone that helps control blood sugar.
Children and adolescents between the ages of 1 and 17 who have recently been diagnosed with ALL or lymphoma and are starting treatment in Denmark can participate in this study. If you decide to join, you can expect to wear a glucose sensor that tracks your blood sugar levels throughout the treatment process. The findings from this study could lead to new guidelines on how to monitor and manage blood sugar levels in young patients, potentially reducing the risk of developing diabetes later in life. If you have any questions about your eligibility or what being part of the study involves, please speak with your healthcare team.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All children and adolescents diagnosed with ALL and Lymphoma and treated according to the established and approved treatment protocols for these diseases in Denmark can be included in the study.
- Exclusion Criteria:
- • Children and adolescents not fulfilling the inclusion criteria.
About Aarhus University Hospital
Aarhus University Hospital is a leading research institution in Denmark, dedicated to advancing medical science and improving patient care through innovative clinical trials. As a key sponsor of clinical research, the hospital integrates cutting-edge technology and multidisciplinary expertise to conduct studies that address critical health challenges. With a commitment to ethical standards and patient safety, Aarhus University Hospital collaborates with a diverse network of academic and industry partners, ensuring that its research initiatives contribute to the global body of medical knowledge and enhance treatment options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aarhus N, , Denmark
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported